INmune Bio

Focus: INmune Bio is an immuno-oncology focused biotechnology company headquartered in Boca Raton, FL, developing immunotherapy candidates for cancer and neurodegenerative diseases. The company operates as a clinical-stage biotech with a diversified pipeline spanning oncology and CNS indications.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About INmune Bio

AI assessmentNot Hiring

No open roles listed right now. Follow INmune Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

XPro1595

Alzheimer Disease

Phase 1

Clinical Trials (1)

NCT03943264A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's

Phase 1

Help build intelligence for INmune Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline with 7 active programs spanning high-value oncology and neurodegenerative disease areas, providing exposure to multiple therapeutic modalities
Lead program XPro1595 has multiple Phase 2 studies in Alzheimer's disease and MCI, offering potential for near-term clinical readouts and validation
Early-stage immuno-oncology platform (INKmune, INB03) in underexplored mechanisms positions the company at the forefront of immunotherapy innovation

Watch Out For

Zero current job openings and no disclosed headcount, suggesting limited near-term hiring and potential resource constraints
Absence of marketed products, published clinical data, and disclosed financials creates visibility risk and runway uncertainty for long-term stability

Generated by Claude from INmune Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

INKmune

Cancer

Phase 1

Clinical Trials (1)

NCT05933070A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

Phase 1

INKmune

Cancer

Phase 1/2

Clinical Trials (1)

NCT06056791Study of INKmune in Patients With mCRPC (CaRe Prostate)

Phase 1/2